Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 8:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,335 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NaCl-saline placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Phase1 First in Human Ascending Dose Study to Evaluate the Safety and Tolerability of FC-12738 in Health Adults

NCT05978908
View directory record Official record
Conditions
Safety Issues, Tolerance
Interventions
FC-12738, Saline
Drug
Lead sponsor
Neurodegenerative Disease Research Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Study of Lung Clearance After Hypertonic Saline Delivery Using the tPAD Device

NCT02141191
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
inhaled hypertonic saline (7%)
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of LY3041658 in Healthy Participants

NCT02148627
View directory record Official record
Conditions
Healthy
Interventions
LY3041658 (SC), LY3041658 (IV), Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 14, 2026, 8:29 AM EDT
Not listed Phase 2 Interventional

Study to Determine if Pre- and Post- Operative TAP Catheters With Ropivacaine Versus Placebo Affects Anesthetic, Narcotic Dosing, and Pain Scores

NCT03149783
View directory record Official record
Conditions
Pain, Postoperative, Delirium, Anesthesia, Local
Interventions
Ropivacaine HCL, sodium chloride
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 27, 2021 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Dose-Finding Trial to Evaluate the Safety and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647 in Healthy Adults

NCT04232280
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
mRNA-1647, Placebo
Biological · Other
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
315 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
9
States / cities
Sacramento, California • Peoria, Illinois • Lenexa, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study to Evaluate if the Drug Vasopressin Protects the Kidneys for Patients Undergoing Liver Transplant

NCT00886262
View directory record Official record
Conditions
Liver Failure
Interventions
Vasopressin, Normal saline placebo
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 2 Interventional

Comparative Study of Coadministered Ceftaroline Fosamil and NXL104 vs. Intravenous Doripenem in Adult Subjects With Complicated Urinary Tract Infections

NCT01281462
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Ceftaroline fosamil and NXL104 (q8h), Ceftaroline fosamil and NXL104 (q12h), Doripenem, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
5
States / cities
La Mesa, California • San Diego, California • Pensacola, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2014 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows

NCT00752050
View directory record Official record
Conditions
Glabellar Rhytides, Frown Lines Between the Eyebrows
Interventions
Mentor Purified Toxin Botulinum Toxin Type A, Preservative-free Saline
Drug
Lead sponsor
Mentor Worldwide, LLC
Industry
Eligibility
18 Years and older
Enrollment
699 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Oct 14, 2026, 8:29 AM EDT
Terminated Phase 4 Interventional Results available

Low Dose Extended-release Epidural and Lumbar Plexus Block Compared to Lumbar Plexus Block for Total Hip Resurfacing

NCT00934661
View directory record Official record
Conditions
Hip Arthroplasty
Interventions
Extended Release Epidural Morphine (EREM), Placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Airway Alkalinization and Nasal Colonization

NCT03078088
View directory record Official record
Conditions
Healthy Subjects, Cystic Fibrosis
Interventions
Tham, Saline
Drug
Lead sponsor
Lakshmi Durairaj
Other
Eligibility
16 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 30, 2020 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19

NCT04843761
View directory record Official record
Conditions
Covid19
Interventions
Remdesivir, Remdesivir Placebo, Aviptadil, Aviptadil Placebo, Corticosteroid
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 14, 2026, 8:29 AM EDT
Recruiting Phase 2 Interventional

Ublituximab in Autoantibody Positive Immune Mediated Necrotizing Myopathy

NCT07103746
View directory record Official record
Conditions
Autoimmune Disorders
Interventions
Ublituximab, Placebo for Ublituximab
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
8
States / cities
Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 3 Interventional Results available

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

NCT03113760
View directory record Official record
Conditions
NLRC4-MAS, XIAP Deficiency
Interventions
Tadekinig alfa, 0.9% sodium chloride
Drug · Other
Lead sponsor
AB2 Bio Ltd.
Industry
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
6
States / cities
La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 14, 2026, 8:29 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Intravesical Apaziquone as a Surgical Adjuvant in Participant Undergoing Transurethral Resection Bladder Tumor (TURBT)

NCT02563561
View directory record Official record
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo
Drug · Other
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Development of Adherence Biomarkers for Multiple Microbicide and Multipurpose Prevention Technology (MPT) Dosage Forms

NCT02569697
View directory record Official record
Conditions
HIV
Interventions
HEC Placebo gel, Placebo Intravaginal Ring, Placebo Vaginal Film, Placebo Vaginal Insert
Other
Lead sponsor
CONRAD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety of mRNA-0184 in Participants With Heart Failure

NCT05659264
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
mRNA-0184, Placebo
Drug
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • Gainesville, Florida • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

NCT06347133
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Plozasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
97
States / cities
Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 14, 2026, 8:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

NCT04173611
View directory record Official record
Conditions
Healthy
Interventions
EXPAREL, Bupivacaine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

NCT02257398
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 14, 2026, 8:29 AM EDT
Terminated Phase 2 Interventional

Study to Evaluate Plasmin for the Creation of a Posterior Vitreous Detachment

NCT00348439
View directory record Official record
Conditions
Vitreoretinal Traction Syndrome
Interventions
Plasmin, Vehicle
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2019 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 3 Interventional

Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease

NCT00625612
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Denufosol Tetrasodium (INS37217) Inhalation Solution, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
5 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
82
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years

NCT00538434
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Reslizumab, Saline
Biological · Other
Lead sponsor
Ception Therapeutics
Industry
Eligibility
5 Years to 18 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2016 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1 Interventional

Drug Discrimination in Methadone-Maintained Humans Study 3

NCT01068847
View directory record Official record
Conditions
Drug Dependence
Interventions
2-4 of the drugs listed below
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2013 · Synced Oct 14, 2026, 8:29 AM EDT
Completed Phase 1Phase 2 Interventional Results available

C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI

NCT02134314
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure, Delayed Graft Function, Ischemic Reperfusion Injury
Interventions
C1 Esterase Inhibitor, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 14, 2026, 8:29 AM EDT